Trial Testing New GLP-1 Drug To Reduce Pain of Peripheral Neuropathy

Making Sense of Diabetes·Nov 17

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A trial is testing a new GLP-1 drug to reduce the pain of peripheral neuropathy. However, reports also indicate that GLP-1 drugs are being explored for other uses, including weight loss and relief from long COVID symptoms, with some showing promise in reducing knee pain and delivering significant weight loss. The role and potential of GLP-1 drugs in treating various conditions appears to be an area of ongoing research and development.

Full coverage

Retatrutide, the newest weight-loss drug, helped people lose 30% of body weight, on par with weight-loss surgery

UCHealth·Jun 16

3 ways GLP-1 drugs could be getting better

The Washington Post·Jun 10

Scripps Research scientists launch new digital clinical trial to test repurposed drug for long COVID symptom relief

Scripps Research·Oct 30

Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial

CNBC·Dec 11

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook

NeurologyLive·Dec 19

View original report at Making Sense of Diabetes ↗

Fetching the latest headlines…